Dawn Health, Novartis Partner on SaMD Platform
Based on a broad portfolio of treatments by Novartis across many chronic diseases, the partnership will be taking a strategic approach to prioritize those diseases which are characterized by high levels of unmet patient needs.
Dawn Health and Novartis have entered into a strategic partnership that is intended to create a platform that enables effective remote monitoring and management of patients with chronic diseases to transform care for both patients and their care teams.
Building on the Dawn Health SaMD platform, a patient mobile application focused on high engagement and user experience with innovative elements like symptom tracking, novel (digital) biomarkers, clinical decision support services, virtual clinic capabilities and other relevant services as they become available, the platform will be tailored to the needs of each in a range of chronic diseases.
Based on a broad portfolio of treatments by Novartis across many chronic diseases, the partnership will be taking a strategic approach to prioritize those diseases which are characterized by high levels of unmet patient needs, uncertainty about current disease state and progression and resulting cautious approaches to treatment.
Dawn Health is the legal manufacturer of the envisioned platform.
REFERENCE: Dawn Health Partners with Leading Pharmaceutical Company to Transform Chronic Care
